Johnson & Johnson MedTech company Ethicon has obtained CE mark approval for its adjunctive haemostatic sealing patch, ETHIZIA.

It was approved as an adjunctive haemostat for disruptive bleeding on internal organs, except neurological and cardiovascular.

Featuring synthetic polymer technology, ETHIZIA is claimed to be the first and only haemostatic matrix that is equally productive and active on both sides.

The sealing patch, designed for maximum adaptability, can be stuffed, rolled, pulled apart, trimmed and tailored to handle minimally invasive and open surgeries.

After regulatory approvals, the company plans to launch this sealing patch in EMEA in the first quarter of next year and in other major markets in Latin America, the Asia-Pacific and North America.

Ethicon Company Group chairman Vladimir Makatsaria said: “As a global leader in surgery, we are committed to empowering healthcare providers to safeguard patients from surgical complications by continuously delivering breakthrough solutions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Disruptive bleeding can contribute to serious complications and with the addition of ETHIZIA to our portfolio, we are well positioned to deliver critical haemostasis solutions for patients.”

Ethicon is focused on developing clinically differentiated surgical technologies and solutions to address the health challenges associated with cancer, metabolic disease and cardiovascular disease.

Last year, the company acquired Netherlands-based GATT Technologies, which utilises differentiated synthetic polymers to develop haemostatic and sealant products for solving complex surgical bleeding and leak challenges.